Stempeutics

Premium

India's first off-the-shelf cell therapy treatment for knee osteoarthritis

One injection will cost Rs 1.25 lakh with effects lasting for two years or more

Updated On: 19 Sep 2022 | 6:10 AM IST

Stempeutics gets DCGI nod for Phase 3 trial to treat Covid patients

Stempeutics said it has received DCGI clearance to conduct Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

Updated On: 18 Jan 2022 | 3:07 PM IST

Cipla partner Stempeutics gets DCGI nod for stem cell-based product

The company's goal is to globalise its product, Stempeucel, for Buerger's Disease, the company's CEO said

Updated On: 30 May 2016 | 2:32 PM IST